Head to Head Analysis: Myovant Sciences (NYSE:MYOV) vs. ImmunoGen (NYSE:IMGN)

Myovant Sciences (NYSE:MYOV) and ImmunoGen (NASDAQ:IMGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Myovant Sciences and ImmunoGen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Myovant Sciences N/A -545.73% -140.77%
ImmunoGen -292.57% -573.09% -51.49%

Insider and Institutional Ownership

40.5% of Myovant Sciences shares are held by institutional investors. Comparatively, 67.8% of ImmunoGen shares are held by institutional investors. 3.0% of Myovant Sciences shares are held by company insiders. Comparatively, 3.8% of ImmunoGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Myovant Sciences has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, ImmunoGen has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500.

Valuation & Earnings

This table compares Myovant Sciences and ImmunoGen’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Myovant Sciences N/A N/A -$273.55 million ($4.09) -1.49
ImmunoGen $53.82 million 9.10 -$168.84 million ($1.18) -2.77

ImmunoGen has higher revenue and earnings than Myovant Sciences. ImmunoGen is trading at a lower price-to-earnings ratio than Myovant Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Myovant Sciences and ImmunoGen, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myovant Sciences 0 0 8 0 3.00
ImmunoGen 1 6 2 0 2.11

Myovant Sciences currently has a consensus price target of $24.17, indicating a potential upside of 296.17%. ImmunoGen has a consensus price target of $3.28, indicating a potential upside of 0.31%. Given Myovant Sciences’ stronger consensus rating and higher possible upside, equities analysts plainly believe Myovant Sciences is more favorable than ImmunoGen.

Summary

ImmunoGen beats Myovant Sciences on 7 of the 13 factors compared between the two stocks.

Myovant Sciences Company Profile

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. Myovant Sciences Ltd. has partnership with Flo Health to create a digital tool to screen for heavy menstrual bleeding. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

ImmunoGen Company Profile

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen, Inc. has collaborations with Roche, Amgen/Oxford BioTherapeutics, sanofi-aventis U. S. LLC, Biotest AG, Bayer HealthCare AG, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Fusion Pharmaceuticals Inc., Debiopharm International SA, Jazz Pharmaceuticals Ireland Limited, and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.